« Back
Sarepta Therapeutics to Present Company Overview at the Wedbush PacGrow Life Sciences Management Access Conference
07/30/12 6:02 PM EDT
Webcast Accessible via Sarepta Therapeutics Website
CAMBRIDGE, MA -- (Marketwire - July 30, 2012) - Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference in New York, NY on Tuesday, August 14, 2012 at 2:30 p.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.
The presentation will be webcast live under the events section of Sarepta Therapeutics' website at http://www.sareptatherapeutics.com/ and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at http://www.sareptatherapeutics.com/.
Sarepta Media and Investor Contact:
Erin Cox
425.354.5140
ecox@sareptatherapeutics.com
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.